Human CD79B Monoclonal Antibody
Produktgrößen
1 mg
£355,00
YR0123-1MG
5 mg
£885,00
YR0123-5MG
20 mg
£2138,00
YR0123-20MG
Über dieses Produkt
- SKU:
- YR0123
- Zusätzliche Namen:
- AGM6|B29|IGB|Igbeta
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human CD79B
- Isotyp:
- IgG1, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0123